SES
22.2.2024 14:26:26 CET | Business Wire | Press release
The Luxembourg Directorate of Defence (DoD) procured two ground stations following a competitive call for tender to enable the Luxembourg Army to improve its resilience by accessing secure satellite communications services, the DoD, SES and HITEC Luxembourg said today.
The ground stations, which will be installed at the Luxembourg Army’s Military Centre in Diekirch, will be used for Luxembourg’s GovSat-1 satellite services in X- and Military Ka-band frequencies, as well as for the Wideband Global Satcom (WGS) system, the backbone of the satellite communications capability of the U.S. DoD.
The addition of the two new ground stations reinforce resiliency and augment the existing Luxembourg Army satcom infrastructure already built by SES and HITEC Luxembourg 10 years ago, bringing the total number of dedicated antennas to four. The new ground stations unlock the strong potential to scale and add interoperability with the NATO partner systems, in line with the country’s defence strategy for the years to come.
Yuriko Backes, Luxembourg Minister of Defence: “Access to secure satellite communications has always been among the priorities and strengths of Luxembourg, allowing the country to reinforce defence capabilities, as well as enabling fulfillment of Luxembourg’s commitments towards the EU and NATO. To keep the upper technological edge, we will continue to leverage Luxembourg’s globally-renowned expertise in the space sector, to increase our resilience, including that of our armed forces.”
“It is an honour for SES to help strengthen the Luxembourg Government’s defence pillar by adding resiliency to its secure satcom,” said Adel Al-Saleh, CEO of SES. “Following the successful implementation of the initial ground stations by the Luxembourg Army, we are delighted to extend its communications infrastructure that leverages Luxembourg’s GovSat-1 and enhances interoperability with the partner systems.”
“We are proud to be part of the project and once again join efforts with SES to help augment Luxembourg’s defence capabilities with resilient and proven technology,” said Philippe Osch, CEO of HITEC Luxembourg. “The ground terminals to be supplied for the Luxembourg Army’s satcom infrastructure are a source of particular pride for us as they combine the latest technological innovations and a track-record of superior “Made in Luxembourg” quality.”
Follow us on:
Twitter | Facebook | YouTube | LinkedIn | Instagram
About SES
SES has a bold vision to deliver amazing experiences everywhere on earth by distributing the highest quality video content and providing seamless data connectivity services around the world. As a leader in global content connectivity solutions, SES owns and operates the world’s only geosynchronous orbit and medium earth orbit (GEO-MEO) constellation of satellites with the unique combination of global coverage and high performance. By leveraging its vast and intelligent, cloud-enabled network, SES delivers high-quality connectivity solutions anywhere on land, at sea or in the air, and is a trusted partner to the world’s leading telecommunications companies, mobile network operators, governments, connectivity and cloud service providers, broadcasters, video platform operators and content owners. SES’s video network carries over 6,400 channels, reaching 369 million households, delivering managed media services for both linear and non-linear content. The company is headquartered in Luxembourg and listed on Paris and Luxembourg stock exchanges (Ticker: SESG). Further information is available at: www.ses.com
About HITEC Luxembourg
HITEC Luxembourg S.A., a 100%-owned Luxembourg company, has developed its business activities in the field of innovative and quality products and services.
HITEC offers high technology solutions covering different business areas: satellite ground segment; specific and standard equipment for testing and measuring of physical properties; traffic management; mission critical; engineering; consulting; software & ICT development and project management. HITEC serves private and public sector customers at a national and international level.
In our daily commitment, know-how, creativity, quality and perseverance are an integral part of HITECs’ undertaking. Enthusiasm for technology and innovation and a dedication to life-long-learning are core elements of our company culture, reflected by our highly qualified and motivated staff.
HITEC is ISO 9001, ISO 14001, ISO 45001 and AQAP 2110 certified and has several labels, such as “SuperDrecksKëscht fir Betriber“ (ISO 14024:2000 Standard), “Entreprise Socialement Responsable”, delivered by the indr, Responsibility Europe, Made in Luxembourg (for most of the products & services) and is signatory of the IMS Diversity Charter and the “Pacte National – Entreprises et Droits de l’Homme Luxembourg”. HITECs’ motto: market-oriented, client-centric and technology driven.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240222299678/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom